Abeona Therapeutics Treats First Patient in Second Cohort of Phase 1/2 Clinical Trial for ABO-101 in Sanfilippo Syndrome Type B (MPS IIIB) May 14, 2019
Abeona Therapeutics Reports First Quarter 2019 Financial Results and Business Highlights May 10, 2019
Abeona Therapeutics Announces Presentation of EB-101 Data at Society for Investigative Dermatology Annual Meeting May 8, 2019
Abeona Therapeutics Reports Preclinical Data Demonstrating Broad Therapeutic Potential of AIM™ Gene Therapy in Retinal Diseases at Association for Research in Vision and Ophthalmology Annual Meeting May 1, 2019
Abeona Therapeutics to Report New Preclinical Data Demonstrating Therapeutic Potential of ABO-401 for Treatment of Cystic Fibrosis at American Society of Gene and Cell Therapy Annual Meeting Apr 30, 2019
Abeona Therapeutics to Present Data for ABO-401 in Cystic Fibrosis and Retinal Disorders at the American Society of Gene and Cell Therapy Annual Meeting Apr 15, 2019
Abeona Therapeutics Receives FDA Fast Track Designation for ABO-101 for Treatment of Sanfilippo Syndrome Type B (MPS IIIB) Apr 4, 2019
Abeona Therapeutics Announces Participation in 8th Annual SVB Leerink Global Healthcare Conference Feb 22, 2019
